On April 21st 2014, BioCentury, The Bernstein Report on BioBusiness published an Emerging Company Profile article entitled "Minoryx: Mediating rare metabolism" regarding Minoryx’s two complementary strategies for developing therapies to treat inherited metabolic diseases involving enzyme deficiencies: identifying small molecule chaperones that can restore mutant enzyme function, and repurposing existing drugs to treat the effects of enzyme deficiency when restoring function is not an option. View Link